TrialBlood advances2025

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.

Ajay K Gopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.